AMP German Cannabis Group Supplier, Pure Life Cannabis, Completes EU-GMP Gap Analysis

Home / Press Release  / AMP German Cannabis Group Supplier, Pure Life Cannabis, Completes EU-GMP Gap Analysis

BERLIN, Germany, September 17, 2019 –– AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028) announces that one of its prospective medical cannabis supplier, Pure Life Cannabis Corp. (“Pure Life”), has completed its European Union Good Manufacturing Practice (“EU-GMP”) gap analysis and will undergo an EU-GMP audit before calendar year-end.  Upon passing the EU-GMP audit, Pure Life will be subject to an EU-GMP inspection and certification by German State officials.    


AMP and Pure Life announced on February 7, 2019 that they had entered into a non-binding memorandum of understanding to purchase up to 1,200 kilograms of EU-GMP medical cannabis flower annually for four years.  Pure Life is a late-stage Health Canada applicant to become a licensed producer (“LP”) of cannabis and has applied for a standard cultivation and processing licences by Health Canada pursuant to the Cannabis Act and Cannabis Regulations to begin cultivation at its fully constructed facility outside Edmonton, Alberta, Canada.


When AMP enters into a supply agreement with a Canadian LP, the LP goes through the “AMP EU-GMP Certification Program” to ensure it will meet the EU-GMP pharmaceutical quality and consistency standards required to export medical cannabis to Germany. Under the AMP EU-GMP Certification Program, AMP provides EU-GMP gap analysis and audit services and once the LP passes an audit AMP arranges for EU-GMP German certification.  In addition, AMP will arrange for the necessary permits and provide logistics, transportation, and other related services to export medical cannabis from Canada to Germany.


EU-GMP certification is an internationally recognized system that ensures all pharmaceutical goods, including medical cannabis, meet the highest consumer health and safety standards. Canadian licensed producers of cannabis production and operating processes do not meet EU-GMP standards and need to be upgraded and receive EU-GMP certification from a German State before being able to export to Germany.


Management Quotes:


Mr. Alex Blodgett, CEO of AMP German Cannabis Group, commented, “AMP continues to work hard towards its goal of becoming a major exporter to Germany by next year as evidenced by our supply agreement with Pure Life.  AMP looks forward to entering into further supply agreements with other early-to-late staged licensed Canadian LPs.”


Dr. Stefan Feuerstein, Managing Director of Alternative Medical Products GmbH (“AMP Germany”), commented, “AMP Germany expects to complete the final steps in obtaining its narcotic import licence by mid-Q4, 2019 and importing from Canada beginning in the first half of 2020.”


About AMP German Cannabis Group Inc. 


AMP German Cannabis Group is the parent company of several European investment subsidiaries focusing on the import of pharmaceutical-grade (EU-GMP) cannabis into Germany predominantly from Canada.  AMP provides EU-GMP gap analysis and audits, logistical, transportation, importation permits and other related services for the importation of medical cannabis into Germany through its AMP EU-GMP German Certification Protocol Program.


For more information, please visit:


Mr. Alex Blodgett, CEO and Director

Telephone: +236-833-1602




Social media links: Twitter, Reddit, LinkedIn, and Facebook. Media Kit:


Cautionary Statements 


This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the shares in the United States. The shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.


This news release contains forward-looking statements that are based on the Company’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the completion of the offering, the timing thereof and the expected use of proceeds from the offering. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.